BiotechTube

Datopotamab Deruxtecan (Dato-DXd) + Steroid Containing Mouthwash

Phase 1Active
0 watching 0 views this weekπŸ’€ Quiet
33
Hype Score

Development Stage

βœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hormone Receptor Positive Breast Cancer

Conditions

Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer

Trial Timeline

Jan 31, 2018 β†’ Jan 1, 2027

NCT ID
NCT03401385

About Datopotamab Deruxtecan (Dato-DXd) + Steroid Containing Mouthwash

Datopotamab Deruxtecan (Dato-DXd) + Steroid Containing Mouthwash is a phase 1 stage product being developed by Daiichi Sankyo for Hormone Receptor Positive Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03401385. Target conditions include Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03401385Phase 1Active

Competing Products

20 competing products in Hormone Receptor Positive Breast Cancer

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
77
Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)Eli LillyPre-clinical
23
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
77
EnzalutamideAstellas PharmaPhase 2
52
Enzalutamide + Placebo (No longer applicable in Open Label study period) + Leuprolide Open LabelAstellas PharmaPhase 3
77
Enzalutamide + PlaceboAstellas PharmaPhase 3
77
YM598Astellas PharmaPhase 2
52
pegylated Somatropin + pegylated Somatropin + Jintropin AQSun PharmaceuticalPhase 2
52
PEG-somatropinSun PharmaceuticalApproved
85
PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
85
PEG-somatropinSun PharmaceuticalPhase 3
77
ONO-4578 + letrozole + Palbociclib + abemaciclibOno PharmaceuticalPhase 1
33
Somatropin + SomatropinEli LillyPhase 3
77
Abemaciclib + Trastuzumab + Fulvestrant + Standard of Care Single Agent ChemotherapyEli LillyPhase 2
52
Somatropin + SomatropinEli LillyPhase 3
77
Abemaciclib + Aromatase Inhibitor + Abemaciclib + FulvestrantEli LillyApproved
85
dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tabletsJiangsu Hengrui MedicinePhase 1
33
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
77
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
33
SHR7280Jiangsu Hengrui MedicinePhase 1
33

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85